141,900 Shares in Kenvue Inc. $KVUE Bought by Cohen Capital Management Inc.

Key Points

• Cohen Capital Management bought a new stake of 141,900 Kenvue shares in Q4, valued at about $2.45 million, and institutional investors collectively own roughly 97.64% of the company.
• Kenvue beat quarterly expectations with $0.27 EPS vs. $0.22 consensus and revenue of $3.78 billion, while analysts maintain an average "Hold" rating and a mean price target of $19.58.
• The company pays a quarterly dividend of $0.2075 (annualized $0.83) for a ~4.8% yield

Cohen Capital Management Inc. purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 141,900 shares of the company's stock, valued at approximately $2,448,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC purchased a new stake in shares of Kenvue during the 3rd quarter worth about $25,000. NBT Bank N A NY increased its stake in shares of Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company's stock valued at $25,000 after purchasing an additional 1,006 shares in the last quarter. Cornerstone Planning Group LLC increased its stake in shares of Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company's stock valued at $25,000 after purchasing an additional 1,361 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in Kenvue by 150.1% in the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company's stock worth $32,000 after purchasing an additional 1,190 shares during the period. Finally, Trust Co. of Vermont raised its holdings in Kenvue by 50.9% in the 3rd quarter. Trust Co. of Vermont now owns 2,385 shares of the company's stock worth $39,000 after purchasing an additional 804 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $17.16 on Friday. The firm has a 50-day simple moving average of $17.98 and a 200-day simple moving average of $17.08. The stock has a market capitalization of $32.90 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 3.89 and a beta of 0.61. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The firm had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. During the same period in the previous year, the business posted $0.26 earnings per share. Kenvue's quarterly revenue was up 3.2% on a year-over-year basis. On average, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Wednesday, February 11th. Kenvue's payout ratio is currently 107.79%.

Analysts Set New Price Targets

Several brokerages have commented on KVUE. Canaccord Genuity Group raised their price objective on Kenvue from $17.00 to $18.00 and gave the company a "hold" rating in a report on Wednesday, February 18th. Barclays upped their target price on Kenvue from $18.00 to $19.00 and gave the stock an "equal weight" rating in a research note on Friday, March 6th. Jefferies Financial Group lowered Kenvue from a "buy" rating to a "hold" rating and decreased their target price for the company from $23.00 to $18.00 in a research report on Friday, January 30th. UBS Group lifted their price target on shares of Kenvue from $17.00 to $19.00 and gave the company a "neutral" rating in a research note on Wednesday, February 18th. Finally, Citigroup boosted their price target on shares of Kenvue from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Wednesday, February 18th. Three equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.